FSLLRY-NH2 TFA
产品介绍 | FSLLRY-NH2 TFA 是蛋白酶激活受体2 (PAR2)抑制剂。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
Treatment with FSLLRY-NH2 (50 μg per rat administered intranasally at 1 hour postresuscitation) significantly improves neurological outcome and reduces the number of degenerating hippocampal neurons after ACA (asphyxial CA). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
Treatment with FSLLRY-NH2 (50 μg per rat administered intranasally at 1 hour postresuscitation) significantly improves neurological outcome and reduces the number of degenerating hippocampal neurons after ACA (asphyxial CA). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (109.77 mM; Need ultrasonic) H2O : 1.43 mg/mL (1.57 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |